FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nadia Harbeck

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Lymph Nodes

Co-author Network

Publications

TOP 3
Nina Ditsch; Monika Graeser; Nadia Harbeck; Isabelle Himsl; Bettina Löhrs; Bettina Toth; Christina Tripp; Andrea Vodermaier; Ingo Bauerfeind; Miriam S Lenhard
A retrospective investigation of women's experience with breast reconstruction after mastectomy.
Matthias Christgen; Oleg Gluz; Nadia Harbeck; Ulrike Nitz; Hans H Kreipe
Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancer.
Christoph Kowalski; Nicole Ernstmann; Nadia Harbeck; Petra Steffen; Rachel Wuerstlein; Holger Pfaff
Health-related quality of life in male breast cancer patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nadia Harbeck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nina Ditsch; Monika Graeser; Nadia Harbeck; Isabelle Himsl; Bettina Löhrs; Bettina Toth; Christina Tripp; Andrea Vodermaier; Ingo Bauerfeind; Miriam S Lenhard
A retrospective investigation of women's experience with breast reconstruction after mastectomy.
Archives of gynecology and obstetrics 2013;287(3):555-61.
2012: Matthias Christgen; Oleg Gluz; Nadia Harbeck; Ulrike Nitz; Hans H Kreipe
Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(26):3313-4; author reply 3314-5.
2012: Christoph Kowalski; Nicole Ernstmann; Nadia Harbeck; Petra Steffen; Rachel Wuerstlein; Holger Pfaff
Health-related quality of life in male breast cancer patients.
Breast cancer research and treatment 2012;133(2):753-7.
2012: Christoph Kowalski; Sophie E Diener; Nadia Harbeck; Petra Steffen; Rachel Wuerstlein; Holger Pfaff
Associations between hospital and patient characteristics and breast cancer patients' satisfaction with nursing staff.
Cancer nursing 2012;35(3):221-8.
2012: Nadia Harbeck; Achim Rody
Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(7):686-9.
2011: Nadia Harbeck
Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management.
Breast cancer research and treatment 2011;130(2):421-3.
2011: Julia Dorn; T Gerte; A Gkazepis; Nadia Harbeck; Antonina Harlozinska; Marion Kiechle; Viktor Magdolen; T Schuster; Pawel Sedlaczek; Eleftherios P Diamandis; Manfred Schmitt
Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(8):1783-90.
2011: Manfred Schmitt; Nils Brünner; Julia Dorn; Nadia Harbeck; Fritz Jänicke; Heike Jansen; Eva J Kantelhardt; Christoph Meisner; Bernd Mühlenweg; Ulrike Nitz; Christoph Thomssen
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert review of molecular diagnostics 2011;11(6):617-34.
2011: Nadia Harbeck; M S Ewer; M De Laurentiis; T M Suter; S M Ewer
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(6):1250-8.
2011: Oleg Gluz; Peter Wild; Cornelia Liedtke; Ronald Kates; Heiko Mendrik; Elisabeth Ehm; Verena Artinger; Raihanatou Diallo-Danebrock; Evelyn Ting; Svjetlana Mohrmann; Christopher Poremba; Nadia Harbeck; Ulrike Nitz; Arndt Hartmann; Andreas Gaumann
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
Breast cancer research and treatment 2011;126(3):643-51.
2011: Julia Dorn; Nadia Harbeck; Ronald Kates; A Gkazepis; Andreas Scorilas; A Soosaipillai; Eleftherios P Diamandis; Marion Kiechle; Barbara Schmalfeldt; Manfred Schmitt
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(4):877-83.
2011: Volker R Jacobs; Marion Kiechle; Stefanie C Mayer; Bernadette J Paessens; Rudolf Bernard; Nadia Harbeck; Angela Ihbe-Heffinger
Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
Onkologie 2011;34(11):614-8.
2011: Nadia Harbeck; Christoph Thomssen
A new look at node-negative breast cancer.
The oncologist 2011;16 Suppl 1():51-60.
2011: Mathias Warm; Ronald Kates; Friedrich Overkamp; Anke Thomas; Nadia Harbeck
Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.
Breast cancer research and treatment 2011;125(1):127-36.
2010: Nadia Harbeck; Marwa Salem; Ulrike Nitz; Oleg Gluz; Cornelia Liedtke
Personalized treatment of early-stage breast cancer: present concepts and future directions.
Cancer treatment reviews 2010;36(8):584-94.
2010: Manfred Schmitt; Karin Mengele; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Apostolos Gkazepis; Fred Sweep; Nils Brünner; John Foekens; Nadia Harbeck
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert review of molecular diagnostics 2010;10(8):1051-67.
2010: Mathias Warm; Ronald Kates; Em Grosse-Onnebrink; M Stoff-Khalili; Markus Hoopmann; Peter Mallmann; Anke Thomas; Nadia Harbeck
Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Anticancer research 2010;30(10):4251-9.
2010: Karin Mengele; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Apostolos Gkazepis; Fred Sweep; Nils Brünner; John Foekens; Nadia Harbeck; Manfred Schmitt
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert review of molecular diagnostics 2010;10(7):947-62.
2010: Silke Steinbach; Walter Hundt; Thomas Zahnert; Sabina Berktold; Christina Böhner; Nina Gottschalk; Moritz Hamann; Monika Kriner; Petra Heinrich; Barbara Schmalfeldt; Nadia Harbeck
Gustatory and olfactory function in breast cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2010;18(6):707-13.
2010: Hans-Joachim Stemmler; Nadia Harbeck; Isolde Gröll de Rivera; Ursula Vehling-Kaiser; G Rauthe; Wolfgang Abenhardt; Almut Artmann; Harald Sommer; Hans-Gerd Meerpohl; Marion Kiechle; Volker Heinemann
Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
Oncology 2010;79(3-4):204-10.
2010: Hans-Joachim Stemmler; Nadia Harbeck; Isolde Gröll de Rivera; Ursula Vehling-Kaiser; G Rauthe; Wolfgang Abenhardt; Almut Artmann; Harald Sommer; Hans-Gerd Meerpohl; Marion Kiechle; Volker Heinemann
Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Oncology 2010;79(3-4):197-203.
2010: Nadia Harbeck; Christoph Thomssen
A new look at node-negative breast cancer.
The oncologist 2010;15 Suppl 5():29-38.
2010: Volker R Jacobs; Linda Rasche; Nadia Harbeck; Mathias Warm; Peter Mallmann
Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG revenues for uni- and bilateral mastectomy with immediate breast reconstruction.
Onkologie 2010;33(11):584-8.
2010: Dimo Dietrich; Manuel Krispin; Jörn Dietrich; Anne Fassbender; Jörn Lewin; Nadia Harbeck; Manfred Schmitt; Serenella Eppenberger-Castori; Vincent Vuaroqueaux; Frédérique Spyratos; John A Foekens; Ralf Lesche; John Martens
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
BMC cancer 2010;10():247.
2009: Oleg Gluz; Karin Mengele; Manfred Schmitt; Ronald Kates; Raihana Diallo-Danebrock; Frauke Neff; Hans-Dieter Royer; Niels Eckstein; Svjetlana Mohrmann; Evelyn Ting; Marion Kiechle; Christopher Poremba; Ulrike Nitz; Nadia Harbeck
Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6144-51.
2009: Katja Specht; Nadia Harbeck; Jan Smida; Katja Annecke; Ulrike Reich; Joerg Naehrig; Rupert Langer; Joerg Mages; Raymonde Busch; Elisabeth Kruse; Ludger Klein-Hitpass; Manfred Schmitt; Marion Kiechle; Heinz Hoefler
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Breast cancer research and treatment 2009;118(1):45-56.
2009: John Martens; Astrid L Margossian; Manfred Schmitt; John Foekens; Nadia Harbeck
DNA methylation as a biomarker in breast cancer.
Future oncology (London, England) 2009;5(8):1245-56.
2009: Michael Braun; Volker R Jacobs; Stefan Wagenpfeil; Daniel Sattler; Nadia Harbeck; Ulrike Nitz; Rudolf Bernard; Walther Kuhn; Angela Ihbe-Heffinger
Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
Onkologie 2009;32(8-9):473-81.
2009: Silke Steinbach; Thomas Hummel; Christina Böhner; Sabina Berktold; Walter Hundt; Monika Kriner; Petra Heinrich; Harald Sommer; Claus Hanusch; Anita Prechtl; Burghart Schmidt; Ingo Bauerfeind; Katharina Seck; Volker R Jacobs; Barbara Schmalfeldt; Nadia Harbeck
Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1899-905.
2009: Ariane Sadr-Nabavi; Juliane Ramser; Juliane Volkmann; Joerg Naehrig; Frank Wiesmann; Beate Betz; Heide Hellebrand; Stefanie Engert; Susanne Seitz; Rene Kreutzfeld; Takako Sasaki; Norbert Arnold; Rita K Schmutzler; Marion Kiechle; Dieter Niederacher; Nadia Harbeck; Edgar Dahl; Alfons Meindl
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.
International journal of cancer. Journal international du cancer 2009;124(7):1727-35.
2009: Oliver Hartmann; Frédérique Spyratos; Nadia Harbeck; Dimo Dietrich; Anne Fassbender; Manfred Schmitt; Serenella Eppenberger-Castori; Vincent Vuaroqueaux; Florence Lerebours; Katrin Welzel; Sabine Maier; Achim Plum; Stephan Niemann; John A Foekens; Ralf Lesche; John Martens
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):315-23.
2008: Nadia Harbeck
Never too late: reducing late breast cancer relapse risk.
Current medical research and opinion 2008;24(12):3295-305.
2008: Nadia Harbeck; Inko Nimmrich; Arndt Hartmann; Jeffrey S Ross; Tanja Cufer; Robert Grützmann; Glen Kristiansen; angelo paradiso; Oliver Hartmann; Astrid Margossian; John Martens; Ina Schwope; Antje Lukas; Volkmar Müller; Karin Milde-Langosch; Jörg Nährig; John A Foekens; Sabine Maier; Manfred Schmitt; Ralf Lesche
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5036-42.
2008: Inko Nimmrich; Anieta M Sieuwerts; Marion E Meijer-Van Gelder; Ina Schwope; Joan Bolt-de Vries; Nadia Harbeck; Thomas Koenig; Oliver Hartmann; Antje Kluth; Dimo Dietrich; Viktor Magdolen; Henk Portengen; Maxime P Look; Jan G M Klijn; Ralf Lesche; Manfred Schmitt; Sabine Maier; John A Foekens; John Martens
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Breast cancer research and treatment 2008;111(3):429-37.
2008: Hans-Joachim Stemmler; Karin Mengele; Manfred Schmitt; Nadia Harbeck; Dorit Laessig; Karin A Herrmann; Pamela Schaffer; Volker Heinemann
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Anti-cancer drugs 2008;19(8):832-6.
2008: Mathias Warm; Caroline Gatermann; Ronald Kates; Peter Mallmann; Stefan Paepke; Nadia Harbeck; Anke Thomas
Postoperative sense of well-being and quality of life in breast cancer patients do not depend on type of primary surgery.
Onkologie 2008;31(3):99-104.
2008: Ambros J Beer; Markus Niemeyer; Janette Carlsen; Mario Sarbia; Jörg Nährig; Petra Watzlowik; Hans-Jürgen Wester; Nadia Harbeck; Markus Schwaiger
Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(2):255-9.
2008: Sibylle Loibl; Gunter von Minckwitz; Nadia Harbeck; Wolfgang Janni; Dirk Elling; Manfred Kaufmann; Holm Eggemann; Valentina Nekljudova; Harald Sommer; Marion Kiechle; Sherko Kümmel
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Breast cancer research : BCR 2008;10(5):R77.
2007: Stefan Paepke; Volker R Jacobs; Ralf Ohlinger; Mathias Warm; Sherko Kümmel; Anke Thomas; Nadia Harbeck; Marion Kiechle-Bahat
Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
Journal of cancer research and clinical oncology 2007;133(12):905-16.
2007: Mathias Warm; Frank Nawroth; Ralf Ohlinger; Markus M Valter; Ellen Pantke; Peter Mallmann; Nadia Harbeck; Ronald Kates; Anke Thomas
Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
Onkologie 2007;30(8-9):436-41.
2007: Sabine Maier; Inko Nimmrich; Thomas Koenig; Serenella Eppenberger-Castori; Inga Bohlmann; angelo paradiso; Frédérique Spyratos; Christoph Thomssen; Volkmar Mueller; Jörg Nährig; Francesco Schittulli; Ronald Kates; Ralf Lesche; Ina Schwope; Antje Kluth; Almuth Marx; John Martens; John A Foekens; Manfred Schmitt; Nadia Harbeck
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
European journal of cancer (Oxford, England : 1990) 2007;43(11):1679-86.
2007: Kristina Lindemann; James Resau; J Nährig; Eric J Kort; B Leeser; K Annecke; Anita Welk; J Schäfer; George Vande Woude; Ernst Lengyel; Nadia Harbeck
Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Histopathology 2007;51(1):54-62.
2007: Julia Dorn; Manfred Schmitt; Ronald Kates; Barbara Schmalfeldt; Marion Kiechle; Andreas Scorilas; Eleftherios P Diamandis; Nadia Harbeck
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1742-8.
2007: Mathias Warm; Ronald Kates; Peter Mallmann; Michèlle Dick; Frank Nawroth; Nadia Harbeck; Stefan Paepke; Anke Thomas
Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
Anticancer research 2007;27(2):1031-8.
2007: Manfred Schmitt; Karin Mengele; Elisabeth Schueren; Fred C G J Sweep; John A Foekens; Nils Brünner; Juliane Laabs; Abha Malik; Nadia Harbeck
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers.
European journal of cancer (Oxford, England : 1990) 2007;43(5):835-44.
2007: Nadia Harbeck; Renate Haidinger
The patient experience.
Breast cancer research and treatment 2007;105 Suppl 1():91-103.
2007: Nadia Harbeck; Manfred Schmitt; Stefan Paepke; Heike Allgayer; Ronald Kates
Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.
Critical reviews in clinical laboratory sciences 2007;44(2):179-201.
2007: Hans-Joachim Stemmler; Manfred Schmitt; Amina Willems; Helga Bernhard; Nadia Harbeck; Volker Heinemann
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Anti-cancer drugs 2007;18(1):23-8.
2007: Razvan T Radulescu; Carla Hufnagel; Peter B Luppa; Heide Hellebrand; Wen-Liang Kuo; Marsha Rich Rosner; Nadia Harbeck; Cecylia Giersig; Alfons Meindl; Manfred Schmitt; Gregor Weirich
Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels.
International journal of oncology 2007;30(1):73-80.
2006: Wolfgang Janni; Marion Kiechle; Harald Sommer; Brigitte Rack; Katja Gauger; M Heinrigs; D Steinfeld; D Augustin; W Simon; Nadia Harbeck; Klaus Friese
Study participation improves treatment strategies and individual patient care in participating centers.
Anticancer research 2006;26(5B):3661-7.
2006: Christoph Thussbas; Jörg Nahrig; Sylvia Streit; Johannes Bange; Monika Kriner; Ronald Kates; Kurt Ulm; Marion Kiechle; Heinz Hoefler; Axel Ullrich; Nadia Harbeck
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(23):3747-55.
2006: Julia Dorn; Nadia Harbeck; Ronald Kates; Viktor Magdolen; Linda Grass; Antoninus Soosaipillai; Barbara Schmalfeldt; Eleftherios P Diamandis; Manfred Schmitt
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Biological chemistry 2006;387(8):1121-8.
2006: Stefan Paepke; Volker R Jacobs; Daniela Paepke; Uta Euler; Jens-Uwe Blohmer; Mathias Warm; Ralf Ohlinger; Torsten Fischer; Marion Kiechle; Nadia Harbeck
Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update.
Onkologie 2006;29(5):210-7.
2006: Hans-Joachim Stemmler; Manfred Schmitt; Nadia Harbeck; A Willems; H Bernhard; D Lässig; S Schoenberg; Volker Heinemann
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Oncology reports 2006;15(5):1373-7.
2006: John A Foekens; David Atkins; Yi Zhang; Fred C G J Sweep; Nadia Harbeck; angelo paradiso; Tanja Cufer; Anieta M Sieuwerts; Dmitri Talantov; Paul Span; Vivianne C G Tjan-Heijnen; Alfredo F Zito; Katja Specht; Heinz Hoefler; Rastko Golouh; Francesco Schittulli; Manfred Schmitt; Louk V A M Beex; Jan G M Klijn; Yixin Wang
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1665-71.
2006: Janna Krol; Stefan Paepke; Volker R Jacobs; Daniela Paepke; Uta Euler; Marion Kiechle; Nadia Harbeck
G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Onkologie 2006;29(4):171-8.
2006: Carla A Borgoño; Tadaaki Kishi; Andreas Scorilas; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1487-93.
2006: Salah-Eddin Al-Batran; Hans-Gerd Meerpohl; Gunter von Minckwitz; Akin Atmaca; Ulrich Kleeberg; Nadia Harbeck; Werner Lerbs; Detlef Hecker; Jalid Sehouli; Alexander Knuth; Elke Jager
Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Oncology 2006;70(2):141-6.
2006: Manfred Schmitt; Alexandra S Sturmheit; Anita Welk; Christel Schnelldorfer; Nadia Harbeck
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
Methods in molecular medicine 2006;120():245-65.
2005: Katharina Seck; Silvia Riemer; Ronald Kates; Tobias Ullrich; Verena Lutz; Nadia Harbeck; Manfred Schmitt; Marion Kiechle; Robert B Diasio; Eva Gross
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5886-92.
2005: Volker R Jacobs; Jutta Thoedtmann; Uta Euler; Stefan Paepke; Thorsten Fischer; Nadia Harbeck; Marion Kiechle
Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care.
Onkologie 2005;28(8-9):441-5.
2005: Karin Mengele; Nadia Harbeck; Ute Reuning; Viktor Magdolen; Manfred Schmitt
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
Hämostaseologie 2005;25(3):301-10.
2005: Wolfgang Janni; Brigitte Rack; Kristina Lindemann; Nadia Harbeck
Detection of micrometastatic disease in bone marrow: is it ready for prime time?
The oncologist 2005;10(7):480-92.
2005: John Martens; Inko Nimmrich; Thomas Koenig; Maxime P Look; Nadia Harbeck; Fabian Model; Antje Kluth; Joan Bolt-de Vries; Anieta M Sieuwerts; Henk Portengen; Marion E Meijer-Van Gelder; Christian Piepenbrock; Alexander Olek; Heinz Höfler; Marion Kiechle; Jan G M Klijn; Manfred Schmitt; Sabine Maier; John A Foekens
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Cancer research 2005;65(10):4101-17.
2005: Amina Willems; Katja Gauger; Cordula Henrichs; Nadia Harbeck
Antibody therapy for breast cancer.
Anticancer research 2005;25(3A):1483-9.
2005: Ernst Lengyel; Dieter Prechtel; James Resau; Katja Gauger; Anita Welk; Kristina Lindemann; Georgia Salanti; Thomas Richter; Beatrice Knudsen; George Vande Woude; Nadia Harbeck
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
International journal of cancer. Journal international du cancer 2005;113(4):678-82.
2004: Michael Untch; Isabelle Himsl; Steffen Kahlert; Hans-Joachim Lueck; Holger Eidtmann; Andreas du Bois; Hans-Gerd Meerpohl; Christoph Thomssen; Nadia Harbeck; Christian Jackisch; R Kreienberg; G Emons; D Wallwiener; W Wiese; G Schaller; Walther Kuhn; Michael Muscholl; M Pauschinger; B Langer
Anthracycline and trastuzumab in breast cancer treatment.
Oncology (Williston Park, N.Y.) 2004;18(14 Suppl 14):59-64.
2004: Nadia Harbeck; Ronald Kates; Manfred Schmitt; Katja Gauger; Marion Kiechle; Fritz Janicke; Christoph Thomassen; Maxime P Look; John A Foekens
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
Clinical breast cancer 2004;5(5):348-52.
2004: Manfred Schmitt; Nadia Harbeck; Maria Grazia Daidone; Nils Brynner; M Joe Duffy; John A Foekens; Fred C G J Sweep
Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.
International journal of oncology 2004;25(5):1397-406.
2004: Christian Schindlbeck; Wolfgang Janni; Naim Shabani; Brigitte Rack; Bernd Gerber; Manfred Schmitt; Nadia Harbeck; Harald Sommer; Stephan Braun; Klaus Friese
Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
Breast cancer research and treatment 2004;87(1):65-74.
2004: Eleftherios P Diamandis; Carla A Borgoño; Andreas Scorilas; Nadia Harbeck; Julia Dorn; Manfred Schmitt
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients.
Clinical biochemistry 2004;37(9):823-9.
2004: Marion E Meijer-Van Gelder; Maxime P Look; Harry A Peters; Manfred Schmitt; Nils Brünner; Nadia Harbeck; Jan G M Klijn; John A Foekens
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Cancer research 2004;64(13):4563-8.
2004: Michael Untch; Holger Eidtmann; Andreas du Bois; Hans-Gerd Meerpohl; Christoph Thomssen; Andreas Ebert; Nadia Harbeck; Christian Jackisch; V Heilman; G Emons; D Wallwiener; W Wiese; Jens-Uwe Blohmer; K Höffken; Walther Kuhn; Peter Reichardt; Michael Muscholl; M Pauschinger; B Langer; Hans-Joachim Lück
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
European journal of cancer (Oxford, England : 1990) 2004;40(7):988-97.
2004: Nadia Harbeck; Ronald Kates; Katja Gauger; Amina Willems; Marion Kiechle; Viktor Magdolen; Manfred Schmitt
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Thrombosis and haemostasis 2004;91(3):450-6.
2004: Andreas Scorilas; Carla A Borgoño; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):678-85.
2003: Nadia Harbeck
[Adjuvant chemotherapy in primary breast cancer].
Onkologie 2003;26 Suppl 7():17-20.
2003: Eleftherios P Diamandis; Carla A Borgoño; Andreas Scorilas; George M Yousef; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2003;24(6):299-309.
2003: George M Yousef; Mary-Ellen Polymeris; Linda Grass; Antoninus Soosaipillai; Pak-Cheung Chan; Andreas Scorilas; Carla A Borgoño; Nadia Harbeck; Barbara Schmalfeldt; Julia Dorn; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Cancer research 2003;63(14):3958-65.
2003: Tadaaki Kishi; Linda Grass; Antoninus Soosaipillai; Andreas Scorilas; Nadia Harbeck; Barbara Schmalfeldt; Julia Dorn; Michal Mysliwiec; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 8, a novel biomarker for ovarian carcinoma.
Cancer research 2003;63(11):2771-4.
2003: Iris Zemzoum; Ronald Kates; Jeffrey S Ross; Peer Dettmar; Moshumi Dutta; Cordula Henrichs; Suna Yurdseven; Heinz Höfler; Marion Kiechle; Manfred Schmitt; Nadia Harbeck
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1022-8.
2003: Jenny Chang-Claude; Alison M Dunning; Udo Schnitzbauer; Petra Galmbacher; Louise Tee; Matthias Wjst; Jennifer Chalmers; Iris Zemzoum; Nadia Harbeck; Paul D P Pharoah; Heidi Hahn
The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk.
International journal of cancer. Journal international du cancer 2003;103(6):779-83.
2003: Ronald Kates; Manfred Schmitt; Nadia Harbeck
Advanced statistical methods for the definition of new staging models.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():101-13.
2003: Frigga Roggel; Stefan Hocke; Kristina Lindemann; Sonja Sinz; Anita Welk; Martin Bosl; Martina Pabst; N Nusser; Stephan Braun; Manfred Schmitt; Nadia Harbeck
Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():89-100.
2002: Nadia Harbeck; Ronald Kates; Maxime P Look; Marion E Meijer-Van Gelder; Jan G M Klijn; Achim Krüger; Marion Kiechle; Fritz Jänicke; Manfred Schmitt; John A Foekens
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Cancer research 2002;62(16):4617-22.
2002: Nadia Harbeck; Manfred Schmitt; Ronald Kates; Marion Kiechle; Iris Zemzoum; Fritz Jänicke; Christoph Thomssen
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clinical breast cancer 2002;3(3):196-200.
2002: Johannes Bange; Dieter Prechtl; Yuri Cheburkin; Katja Specht; Nadia Harbeck; Manfred Schmitt; Tatjana Knyazeva; Susanne Müller; Silvia Gärtner; Irmi Sures; Hongyang Wang; Evgeny Imyanitov; Hans-Ulrich Häring; Pjotr Knayzev; Stefano Iacobelli; Heinz Höfler; Axel Ullrich
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Cancer research 2002;62(3):840-7.
2002: Martin Janz; Nadia Harbeck; Peer Dettmar; Ursula Berger; Anja Schmidt; Karsten Jürchott; Manfred Schmitt; hans-dieter royer
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
International journal of cancer. Journal international du cancer 2002;97(3):278-82.
2002: Christian Schindlbeck; Wolfgang Janni; P Schaffer; Naim Shabani; Manfred Schmitt; Nadia Harbeck; Harald Sommer; Stephan Braun
[Tumor biology of primary breast cancer and minimal residual disease].
Acta medica Austriaca. Supplement 2002;59():27-31.
2001: Nadia Harbeck; U Alt; U Berger; Achim Krüger; Christoph Thomssen; Fritz Jänicke; Heinz Höfler; Ronald Kates; Manfred Schmitt
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2757-64.
2001: S Braun; Robert Rosenberg; Stefan Thorban; Nadia Harbeck
Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer.
Seminars in surgical oncology 2001;20(4):334-46.
2001: Nadia Harbeck; A Krüger; S Sinz; Ronald Kates; Christoph Thomssen; Manfred Schmitt; Fritz Jänicke
Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
Onkologie 2001;24(3):238-44.
2001: Dieter Prechtel; Nadia Harbeck; U Berger; Heinz Höfler; AK Werenskiold
Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast cancer.
Laboratory investigation; a journal of technical methods and pathology 2001;81(2):159-65.
2000: Matthias Kotzsch; Thomas Luther; Nadia Harbeck; Detlef Ockert; Verena Lutz; Frank Noack; D Grossmann; Sybille Albrecht; Michael D Kramer; A Lossnitzer; Marianne Grosser; Manfred Schmitt; Viktor Magdolen
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
International journal of oncology 2000;17(4):827-34.
2000: A Schnelzer; Dieter Prechtel; U Knaus; K Dehne; Markus Gerhard; Henner Graeff; Nadia Harbeck; Manfred Schmitt; Ernst Lengyel
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.
Oncogene 2000;19(26):3013-20.
2000: AK Werenskiold; Dieter Prechtel; Nadia Harbeck; Heinz Höfler
Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancer.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2000;9(1):26-34.
2000: Nadia Harbeck; Ronald Kates; K Ulm; Henner Graeff; Manfred Schmitt
Neural network analysis of follow-up data in primary breast cancer.
The International journal of biological markers 2000;15(1):116-22.
2000: Frank Noack; Manfred Schmitt; J Bauer; D Helmecke; W Krüger; Stefan Thorban; Michael Sandherr; W Kuhn; Henner Graeff; Nadia Harbeck
A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.
The International journal of biological markers 2000;15(1):100-4.
2000: Nadia Harbeck; U Alt; U Berger; Ronald Kates; Achim Krüger; Christoph Thomssen; Fritz Jänicke; Henner Graeff; Manfred Schmitt
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
The International journal of biological markers 2000;15(1):79-83.
2000: A Prechtl; Nadia Harbeck; Christoph Thomssen; C Meisner; M Braun; Michael Untch; M Wieland; BW Lisboa; T Cufer; Henner Graeff; K Selbmann; Manfred Schmitt; Fritz Jänicke
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
The International journal of biological markers 2000;15(1):73-8.
1999: Frank Noack; D Helmecke; Robert Rosenberg; Stefan Thorban; Hjalmar Nekarda; U Fink; J Lewald; M Stich; K Schutze; Nadia Harbeck; Viktor Magdolen; Henner Graeff; Manfred Schmitt
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
International journal of oncology 1999;15(4):617-23.
1999: Nadia Harbeck; P Dettmar; Christoph Thomssen; U Berger; Kurt Ulm; Ronald Kates; Heinz Höfler; Fritz Jänicke; Henner Graeff; Manfred Schmitt
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
British journal of cancer 1999;80(3-4):419-26.
1999: W Kuhn; Barbara Schmalfeldt; Ute Reuning; L Pache; U Berger; Kurt Ulm; Nadia Harbeck; K Späthe; P Dettmar; Heinz Höfler; Fritz Jänicke; Manfred Schmitt; Henner Graeff
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
British journal of cancer 1999;79(11-12):1746-51.
1999: Nadia Harbeck; J S Ross; S Yurdseven; P Dettmar; M Pölcher; W Kuhn; Kurt Ulm; Henner Graeff; Manfred Schmitt
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
International journal of oncology 1999;14(4):663-71.
1999: Nadia Harbeck; Christoph Thomssen; U Berger; Kurt Ulm; Ronald Kates; Heinz Höfler; Fritz Jänicke; Henner Graeff; Manfred Schmitt
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Breast cancer research and treatment 1999;54(2):147-57.
1998: K Fischer; Verena Lutz; Olaf G Wilhelm; Manfred Schmitt; Henner Graeff; P Heiss; T Nishiguchi; Nadia Harbeck; Horst Kessler; Thomas Luther; Viktor Magdolen; Ute Reuning
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
FEBS letters 1998;438(1-2):101-5.
1998: Nadia Harbeck; P Dettmar; Christoph Thomssen; B Henselmann; W Kuhn; Kurt Ulm; Fritz Jänicke; Heinz Höfler; Henner Graeff; Manfred Schmitt
Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Anticancer research 1998;18(3C):2187-97.
1998: Christoph Thomssen; P Oppelt; Fritz Jänicke; Kurt Ulm; Nadia Harbeck; Heinz Höfler; W Kuhn; Henner Graeff; Manfred Schmitt
Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Anticancer research 1998;18(3C):2173-80.
1997: Manfred Schmitt; Nadia Harbeck; Christoph Thomssen; Olaf G Wilhelm; Viktor Magdolen; Ute Reuning; Kurt Ulm; Heinz Höfler; Fritz Jänicke; Henner Graeff
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Thrombosis and haemostasis 1997;78(1):285-96.
1997: Manfred Schmitt; Christoph Thomssen; Kurt Ulm; A Seiderer; Nadia Harbeck; Heinz Höfler; Fritz Jänicke; Henner Graeff
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
British journal of cancer 1997;76(3):306-11.
1997: P Dettmar; Nadia Harbeck; Christoph Thomssen; L Pache; P Ziffer; K Fizi; Fritz Jänicke; WB Nathrath; Manfred Schmitt; Henner Graeff; Heinz Höfler
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.
British journal of cancer 1997;75(10):1525-33.
1995: Nadia Harbeck; P Dettmar; Christoph Thomssen; L Pache; P Ziffer; K Fizi; Fritz Jänicke; W Nathrath; Manfred Schmitt; Henner Graeff
[Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma].
Gynäkologisch-geburtshilfliche Rundschau 1995;35 Suppl 1():142-7.
1994: T Nakamura; H Nekarda; A H Hoelscher; Elfriede Bollschweiler; Nadia Harbeck; K Becker; Jörg Rüdiger Siewert; N ] Harbec N [corrected to Harbeck
Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.
Cancer 1994;73(7):1785-94.
1994: Nadia Harbeck; Michael Untch; L Pache; W Eiermann
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
British journal of cancer 1994;69(3):566-71.
1993: Fritz Jänicke; M Schmitt; L Pache; Kurt Ulm; Nadia Harbeck; Heinz Höfler; Henner Graeff
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Breast cancer research and treatment 1993;24(3):195-208.
1993: Michael Untch; C Nestle-Krämling; Gottfried E Konecny; Nadia Harbeck; Ilona Funke; Rainer Kimmig; Hermann Hepp
[Prognostic value of tumor cells in bone marrow in breast cancer].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():308-10.
1993: Nadia Harbeck; E Schüren; N Yamamoto; L Pache; Manfred Schmitt; Fritz Jänicke; P Dettmar; Heinz Höfler; Henner Graeff
[DNA flow cytometric analysis in primary breast cancer. S-phase and ploidy status as prognostic factors and their correlation to tumor-associated proteolytic factors].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():303-4.
1993: Nadia Harbeck; E Schüren; N Yamamoto; Manfred Schmitt; Heinz Höfler; Henner Graeff
[Development of a technique for isolation of intact tumor cells from fresh breast or ovarian cancer tissue. Use in analysis of tumor-associated proteolytic factors].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():277-9.
1991: Nadia Harbeck; N Moniwa; E Busch; M Schmitt; Fritz Jänicke; C Fellbaum; H Höfler; Henner Graeff
[Flow cytometry DNA analysis of pure cell nuclei from formalin fixed paraffin sections in primary breast cancer: correlation with other prognostic factors].
Gynäkologische Rundschau 1991;31 Suppl 2():299-302.
1990: W Eiermann; Nadia Harbeck; Michael Untch
[Possibilities in immunocytochemistry exemplified by bone marrow aspiration cytology in patients with breast carcinoma].
Der Gynäkologe 1990;23(6):358-64.
1989: M Untch; Nadia Harbeck; W Eiermann
[Micrometastases in bone marrow at the time of primary treatment of breast cancer: a new prognostic criterion?].
Gynäkologische Rundschau 1989;29 Suppl 2():231-3.
1988: M Untch; Nadia Harbeck; W Eiermann
Micrometastases in bone marrow in patients with breast cancer.
British medical journal (Clinical research ed.) 1988;296(6617):290.